News

Scientists at St. Jude Children’s Research Hospital improved bispecific chimeric antigen receptor (CAR) T–cell immunotherapies for acute myeloid leukemia (AML), corroborated by computational analysis.

A study by University of Pennsylvania researchers shows that secondary cancer development is rare after CAR T-cell therapy and that many patients have achieved long-lasting remission.

An initial trial suggests a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome resulting from Covid-19.

Current immunotherapies work only against cancers of the blood and bone marrow. T cells engineered by Northwestern and UCSF were able to kill tumors derived from skin, lung and stomach in mice.

Researchers have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness of the breast cancer drug T-DM1 if the cancer cells have developed resistance.

Blood tests could predict outcomes of CAR T-cell therapy, helping to optimize cancer treatments and improve their safety and efficacy.

A new therapeutic for stroke based on University of Georgia research will soon enter clinical trials. The U.S. Food and Drug Administration cleared the new drug to enter a Phase 1b/2a clinical trial.

Results from a Phase 3 clinical trial show that the vaccine is safe and effective for those aged 2–59 regardless of whether they have previously been infected with dengue.

A single dose of a CRISPR/Cas9 therapy has been successful in treating hereditary angioedema, reports an initial study of ten patients.

Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.